An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Expanded access is currently available for this treatment.
Verified March 2013 by Eisai Inc.
Sponsor:
Eisai Inc.
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01240421
First received: October 1, 2010
Last updated: March 3, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | Expanded access is currently available for this treatment. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |